Brayden Brandvold

Galectin-1 therapy recalibrates lipid remodeling in skeletal muscle and enhances muscle function in a model of LGMD2B/R2

Limb-Girdle Muscular Dystrophy type 2B/R2 (LGMD2B/R2) is a progressive myopathy caused by mutations in the DYSF gene, leading to dysferlin deficiency, impaired membrane repair, chronic inflammation, and lipid accumulation. No approved treatments currently exist. Galectin-1, a red...